Efficacy of R±BEACOP regimen in patients with
poor-prognosis lymphoma / 中南大学学报(医学版)
Journal of Central South University(Medical Sciences)
; (12): 858-863, 2015.
Article
em Zh
| WPRIM
| ID: wpr-815258
Biblioteca responsável:
WPRO
ABSTRACT
OBJECTIVE@#To analyze the efficacy of cyclophosphamideplus, epirubicin, vincristine, prednisone plus etoposide and/or bleomycin, with or without rituximab (R±BEACOP) regimen in patient with poor-prognosis lymphoma.
@*METHODS@#A total of 89 patients, who had poor-prognosis lymphoma and received at least 1 cycle of R±BEACOP regimen during 2002 to 2012, were enrolled and analyzed by a retrospective study.
@*RESULTS@#The rate of complete response was 62.9% (56 patients). The efficacy of Hodgkin lymphoma (HL) and T/NK NHL was better than that of other types of lymphoma. There was no significant difference in efficacy among the patients with different age, stage or international prognosis index (IPI) (all P>0.05).
@*CONCLUSION@#R±BEACOP regimen is effective in some patients with poor prognosis, especially in HL patients. Thus, multicenter prospective study regarding the R±BEACOP regimen needs to be done to further test its efficacy.
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Procarbazina
/
Prognóstico
/
Vincristina
/
Bleomicina
/
Prednisona
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Doxorrubicina
/
Estudos Retrospectivos
/
Classificação
/
Ciclofosfamida
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
Limite:
Humans
Idioma:
Zh
Revista:
Journal of Central South University(Medical Sciences)
Ano de publicação:
2015
Tipo de documento:
Article